Genomic Profiling of Prostate Cancers from Men with African and European Ancestry.
Adult
Black or African American
/ genetics
Aged
Aged, 80 and over
Biomarkers, Tumor
/ genetics
DNA Copy Number Variations
DNA Mutational Analysis
/ statistics & numerical data
DNA Repair
Datasets as Topic
Genomics
/ statistics & numerical data
Health Status Disparities
Humans
Incidence
Male
Middle Aged
Mutation
Neoplasm Grading
Prostatic Neoplasms
/ diagnosis
White People
/ genetics
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 09 2020
01 09 2020
Historique:
received:
17
12
2019
revised:
07
04
2020
accepted:
08
06
2020
pubmed:
12
7
2020
medline:
26
11
2021
entrez:
12
7
2020
Statut:
ppublish
Résumé
African American (AFR) men have the highest mortality rate from prostate cancer (PCa) compared with men of other racial/ancestral groups. Differences in the spectrum of somatic genome alterations in tumors between AFR men and other populations have not been well-characterized due to a lack of inclusion of significant numbers in genomic studies. To identify genomic alterations associated with race, we compared the frequencies of somatic alterations in PCa obtained from four publicly available datasets comprising 250 AFR and 611 European American (EUR) men and a targeted sequencing dataset from a commercial platform of 436 AFR and 3018 EUR men. Mutations in Although we identified some novel differences in AFR men compared with other populations, the frequencies of genomic alterations in current therapeutic targets for PCa were similar between AFR and EUR men, suggesting that existing precision medicine approaches could be equally beneficial if applied equitably.
Identifiants
pubmed: 32651179
pii: 1078-0432.CCR-19-4112
doi: 10.1158/1078-0432.CCR-19-4112
pmc: PMC7597977
mid: NIHMS1604408
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
4651-4660Subventions
Organisme : NCI NIH HHS
ID : P20 CA233255
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA214253
Pays : United States
Organisme : NCI NIH HHS
ID : F30 CA250248
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008152
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM144295
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Prostate. 2013 May;73(6):590-5
pubmed: 23060014
J Clin Oncol. 2019 Feb 10;37(5):403-410
pubmed: 30576268
Prostate Cancer Prostatic Dis. 2020 Sep;23(3):517-526
pubmed: 32111923
Cancer Discov. 2017 Sep;7(9):973-983
pubmed: 28515055
Saudi J Med Med Sci. 2019 Jan-Apr;7(1):16-21
pubmed: 30787852
PLoS One. 2015 Nov 23;10(11):e0143515
pubmed: 26599344
Cancer Discov. 2014 Apr;4(4):405-14
pubmed: 24658082
JAMA Oncol. 2019 Jul 1;5(7):975-983
pubmed: 31120534
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28825054
Cell Syst. 2018 Mar 28;6(3):271-281.e7
pubmed: 29596782
Clin Cancer Res. 2014 Sep 15;20(18):4925-34
pubmed: 25056375
JAMA. 2018 Dec 18;320(23):2479-2481
pubmed: 30561471
Lancet Oncol. 2015 Jan;16(1):25-35
pubmed: 25524798
Hum Pathol. 2013 Aug;44(8):1617-23
pubmed: 23574779
Cancer Cell. 2018 Oct 8;34(4):549-560.e9
pubmed: 30300578
Nature. 2020 Apr;580(7801):93-99
pubmed: 32238934
J Natl Cancer Inst. 2001 Mar 7;93(5):388-95
pubmed: 11238701
Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14068-73
pubmed: 16945910
J Natl Cancer Inst. 1997 Jan 15;89(2):158-65
pubmed: 8998185
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Medicines (Basel). 2019 Jul 30;6(3):
pubmed: 31366128
Nature. 2017 Jun 29;546(7660):671-675
pubmed: 28614298
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Urol Oncol. 2017 Aug;35(8):535
pubmed: 28623072
JAMA Oncol. 2016 Aug 1;2(8):1070-4
pubmed: 27366979
Neoplasia. 2014 May;16(5):377-89
pubmed: 24934715